Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib with temozolomide + irinotecan versus temozolomide + irinotecan in relapsed or refractory Ewing sarcoma
MOH_2023-04-18_010448Phase 2Not yet recruiting
- Sponsor
- Pfizer
- Start
- Mar 2023
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Ewing sarcoma comparing Palbociclib in combination with temozolomide and irinotecan with Temozolomide and irinotecan alone (2 arms). Primary endpoint: Efficacy comparison of palbociclib + temozolomide + irinotecan versus temozolomide + irinotecan. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
palbociclibtemozolomideirinotecan
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on MOH_2023-04-18_010448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-18_010448.